Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A Shiba-Ishii, TW Johnson, I Dagogo-Jack… - Nature cancer, 2022 - nature.com
Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …
被引用次数：28 相关文章

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

A Shiba-Ishii, TW Johnson, I Dagogo-Jack… - Nature Cancer, 2022 - europepmc.org
Lorlatinib is currently the most advanced, potent and selective ALK tyrosine kinase inhibitor
(TKI) for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the clinic …

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A Shiba-Ishii, TW Johnson, I Dagogo-Jack… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …
[HTML] nih.gov

[HTML][HTML] Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A Shiba-Ishii, TW Johnson, I Dagogo-Jack… - Nature …, 2022 - ncbi.nlm.nih.gov
Lorlatinib is currently the most advanced, potent and selective ALK tyrosine kinase inhibitor
(TKI) for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the clinic …

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

A Shiba-Ishii, TW Johnson, I Dagogo-Jack… - Nature Cancer, 2022 - europepmc.org
Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …